Fluorodeoxyglucose (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 84 | サルコイドーシス | 4 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03048097 (ClinicalTrials.gov) | February 1, 2017 | 2/2/2017 | Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 | Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac Sarcoidosis | Sarcoidosis | Drug: Fluorodeoxyglucose;Drug: Rubidium;Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging | Yale University | NULL | Completed | 18 Years | N/A | All | 15 | Early Phase 1 | United States |
| 2 | EUCTR2015-001815-11-FI (EUCTR) | 19/04/2016 | 29/12/2015 | PET imaging of pulmonary sarcoidosis | Imaging of active granulomas with [18F]FDG and selected inflammatory PET tracers in pulmonary sarcoidosis | Pulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical evidence or biopsy. MedDRA version: 18.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-fluorodeoxyglucose Product Code: FDG INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE Product Name: C11-methionine INN or Proposed INN: L-methionine Other descriptive name: L-METHIONINE ([11C]METHYL) Product Name: 68Ga-DOTANOC INN or Proposed INN: DOTANOC Other descriptive name: DOTANOC | Turku PET Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Finland | ||||
| 3 | NCT01764191 (ClinicalTrials.gov) | January 2013 | 3/1/2013 | 18F-FDG PET Imaging in Cardiac Sarcoidosis | [18 F]-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) in Cardiac Sarcoidosis | Cardiac Sarcoidosis | Other: 18F-Fluorodeoxyglucose (18F-FDG) PET/CT | British Columbia Cancer Agency | NULL | Approved for marketing | 19 Years | N/A | All | Canada | ||
| 4 | JPRN-UMIN000006533 | 2010/04/01 | 30/10/2011 | Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects | sarcoidosis | All patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Echo) before starting corticosteroid therapy and repeat study at 4 weeks after starting corticosteroid therapy. These patients will also have reevaluation 6 to 12 month after the second evaluations. Sarcoidosis without cardiac involvement will undergo steroid treatment will also repeat the same measurements 4 weeks after the treatment. Cardiac sarcoidosis but will not have steroid treatment will also repeat the same measurements 12 months later. Sarcoidosis patients without steroid treatment will also repeat the same measurements 12 months later. Cardiac sarcoidosis with steroid treatment. Cardiac sarcoidosis without steroid treatment. arcoidosis without cardiac involvement who will have steroid treatement. Sarcoidosis without cardiac involvement who will not have steroid treatement. Normal control. | Hokkaido University Graduate School of Medicine | ,NULL | Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not applicable | Japan |